Paroxetine efficacy in the treatment of generalized anxiety disorder

Acta Psychiatrica Scandinavica

Volumn 95, Issue 5, 1997, Pages 444-450

  Rocca, P ^a   Fonzo, V ^a   Scotta, M ^a   Zanalda, E ^a   Ravizza, L ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

benzodiazepines; generalized anxiety disorder; imipramine; paroxetine

Indexed keywords

ADULT; AGED; ARTICLE; DEPRESSION; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NARCISSISM; PATIENT MONITORING; PERSONALITY DISORDER; PRIORITY JOURNAL;

EID: 0030908650     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb09660.x     Document Type: Article

References (30)

1. RICKELS K, CASE WG, DOWNING RW, WINOKUR A. Long-term diazepam therapy and clinical outcome. JAMA 1983: 250: 767-771.
2. SHADER RI, GREENBLATT DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993: 328: 1398-1405.
3. RICKELS K, WISEMAN K, NORSTAD N et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982: 43: 81-86.
4. JOHNSTONE EC, CUNNINGHAM OWENS DG, FRITH CD et al. Neurotic illness and its response to anxiolytic and anti-depressant treatment. Psychol Med 1980: 10: 321-328.
5. KAHN RJ, MCNAIR DM, LIPMAN RS et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious out-patients. Arch Gen Psychiatry 1986: 43: 79-85.
6. HOEHN-SARIC R, MCLEOO DR, ZIMMERLI WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic vs. psychic symptoms. J Clin Psychiatry 1988: 49: 293-301.
7. RICKELS K, DOWNING R, SCHWEIZER E, HASSMAN H. Anti-depressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993: 50: 884-895.
8. KLEIN DF, ZITRIN CM, WOERNER M. Antidepressants, anxiety, panic, and phobia. In: LIPTON MA et al., ed. Psychopharmacology: a generation of progress. New York: Raven Press, 1978: 1401-1410.
9. SHEEHAN DV, BALLENGER J, JACOBSEN G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980: 37: 51-59.
10. MAVISSAKALIAN MR, PEREL JM. Imipramine dose-response relationship in panic disorder with agoraphobia: preliminary findings. Arch Gen Psychiatry 1989: 46: 127-131.
11. PATO MT, ZOHAR J. Current treatment of obsessive-compulsive disorder. Washington, DC: American Psychiatric Press, 1991.
12. RAVIZZA L, BARZEGA G, BELLINO S, BOGETTO F, MAINA G. Drug treatment of obsessive-compulsive disorder: long-term trial with clomipramine and selective serotonin reuptake inhibitors. Psychopharmacol Bull 1996: 32: 167-173.
13. KLEIN DF, RABKIN JG, GORMAN JM. Etiological and pathophysiological inferences from the pharmacological treatment of anxiety. In: TUMA AH, MASER J, ed. Anxiety and the anxiety disorders. Hillsdale, NJ: Lawrence Erlbaum, 1985: 501-532.
14. BROWN TA, BARLOW DH, LIEBOWITZ MR. The empirical basis of generalized anxiety disorder. Am J Psychiatry 1994: 151: 1272-1280.
15. RICKELS K, SCHWEIZER E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacology 1990: 10: 101S-110S.
16. Abacus Concepts Inc. StatView 512+™ for Macintosh. The Interactive Statistics and Graphics Package. Version 1.2. Berkeley, CA: Abacus Concepts Inc., 1988.
17. BALLENGER JC, BURROWS GD, DUPONT RL JR et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988: 45: 413-422.
18. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 1992: 160: 191-202.
19. BROWN TA, BARLOW DH. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 1992: 60: 835-844.
20. BRAWMAN-MINTZER O, LYDIARD RB, EMMANUEL N et al. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993: 150: 1216-1218.
21. MASSION AO, WARSHAW MG, KELLER MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 1993: 150: 600-607.
22. RICKELS K, CSANALOSI I, CHUNG HR, CASE WG, PEREIRA-OGAN JA, DOWNING RW. Amitriptyline in anxious-depressed out-patients: a controlled study. Am J Psychiatry 1974: 131: 25-30.
23. SHAMAS E. Controlled comparison of bromazepam, amitriptyline and placebo in anxiety-depressive neurosis. Dis Nerv Syst 1977: 38: 201-207.
24. HASKELL DS, GAMBILL JD, GARDOS G, MCNAIR DM, FISHER S. Doxepin or diazepam for anxious and anxious-depressed out-patients. J Clin Psychiatry 1978: 39: 135-139.
25. KLEBER RJ. A double-blind comparative study of desipramine hydrochloride and diazepam in the control of mixed anxiety/depression symptomatology. J Clin Psychiatry 1979: 40: 165-170.
26. MCNAIR DM, KAHN RJ. Imipramine compared with benzodiazepine for agoraphobia. In: KLEIN DF, RABKIN J, ed. Anxiety: new research and changing concepts. New York: Raven Press, 1981: 69-80.
27. INSEL TR, MURPHY DL, COHEN RM, ALTERMAN I, KILTS C, LINNOILA M. Obsessive-compulsive disorder. Arch Gen Psychiatry 1983: 40: 605-612.
28. SCHWEIZER E. Generalized anxiety disorder: longitudinal course and pharmacological treatment. In: POLLACK MH, OTTO MW, ed. The psychiatric clinics of North America: anxiety disorders, longitudinal course and treatment. Philadelphia: W.B. Saunders Company, 1995: 843-857.
29. LANE R, BALDWIN D, PRESKORN S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacology 1995: 9 (Suppl. 2): 163-178.
30. SHELDON H, PRESKORN S. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazadone, paroxetine, sertraline and venlafaxine. J Clin Psychiatry 1995: 56 (Suppl. 6): 12-21.